Antibody Therapy for Patients with Lymphoid Malignancies: Past and Present

被引：0

作者：

Naman, Jacob ^{[1
]}

Shah, Nirja ^{[2
]}

Heyman, Benjamin M. ^{[3
]}

机构：

[1] UC San Diego Hlth, Dept Med, La Jolla, CA 92037 USA

[2] UCSD, Sch Med, La Jolla, CA 92037 USA

[3] UC San Diego Hlth, Div Regenerat Med, Dept Med, La Jolla, CA 92037 USA

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2025年 / 26卷 / 04期

关键词：

antibody; malignancy; CLL; FL; DLBCL; rituximab; obinutuzumab; polatuzumab; mosunetuzumab; epcoritamab; CHRONIC LYMPHOCYTIC-LEUKEMIA; ANTI-CD20; MONOCLONAL-ANTIBODY; PHASE-II TRIAL; MAGROLIMAB PLUS RITUXIMAB; LOW-TUMOR BURDEN; FOLLICULAR LYMPHOMA; OPEN-LABEL; LONCASTUXIMAB TESIRINE; BRENTUXIMAB VEDOTIN; 1ST-LINE TREATMENT;

D O I：

10.3390/ijms26041711

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Antibody therapies are a crucial component of modern lymphoid malignancy treatment and an exciting area of active research. We performed a review of modern antibody therapies used in the treatment of lymphoid malignancies, with an emphasis on landmark studies and current directions. We describe the indications for rituximab, obinutuzumab, ADCs, and bispecific antibody therapies. Finally, we summarize early data from ongoing trials on emerging novel therapy combination regimens and discuss the role of machine learning in future therapy development.

引用

页数：21

共 50 条

[21] EFFECTS OF CAMPATH-1 ANTIBODIES INVIVO IN PATIENTS WITH LYMPHOID MALIGNANCIES - INFLUENCE OF ANTIBODY ISOTYPE
DYER, MJS
HALE, G
HAYHOE, FGJ
WALDMANN, H
BLOOD, 1989, 73 (06) : 1431 - 1439
[22] Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders
Robak, Tadeusz
CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2008, 10 (03) : 294 - 309
[23] Emerging antibody-drug conjugates for treating lymphoid malignancies
Wolska-Washer, Anna
Robak, Pawel
Smolewski, Piotr
Robak, Tadeusz
EXPERT OPINION ON EMERGING DRUGS, 2017, 22 (03) : 259 - 273
[24] Monoclonal Antibody Therapy in Haematological Malignancies
Chamuleau, Martine E. D.
van de Loosdrecht, Arjan A.
Huijgens, Peter C.
CURRENT CLINICAL PHARMACOLOGY, 2010, 5 (03): : 148 - 159
[25] Monoclonal antibody therapy of haematological malignancies
Dearden, C
BIODRUGS, 2002, 16 (04) : 283 - 301
[26] Monoclonal Antibody Therapy of Haematological Malignancies
Claire Dearden
BioDrugs, 2002, 16 : 283 - 301
[27] Denileukin diftitox as novel targeted therapy for lymphoid malignancies
Wong, Bryan Y.
Gregory, Stephanie A.
Dang, Nam H.
CANCER INVESTIGATION, 2007, 25 (06) : 495 - 501
[28] Cancer immune therapy for lymphoid malignancies: recent advances
Uffe Klausen
Nicolai Grønne Dahlager Jørgensen
Jacob Handlos Grauslund
Morten Orebo Holmström
Mads Hald Andersen
Seminars in Immunopathology, 2019, 41 : 111 - 124
[29] CpG oligodeoxynucleotide-based therapy of lymphoid malignancies
Weiner, George J.
ADVANCED DRUG DELIVERY REVIEWS, 2009, 61 (03) : 263 - 267
[30] Cancer immune therapy for lymphoid malignancies: recent advances
Klausen, Uffe
Jorgensen, Nicolai Gronne Dahlager
Grauslund, Jacob Handlos
Holmstrom, Morten Orebo
Andersen, Mads Hald
SEMINARS IN IMMUNOPATHOLOGY, 2019, 41 (01) : 111 - 124

← 1 2 3 4 5 →